Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Reviewing Data Related to Drug Used in Fatal Study in France

By Drug Discovery Trends Editor | January 27, 2016

The U.S. Food and Drug Administration is conferring with European regulators after a phase 1 clinical study, conducted by French clinical research organization Biotrial, resulted this week in the death of one enrolled subject and neurological injury to four others.

The study had focused on BIA 10-2474, an investigational new drug (IND) manufactured by Portuguese company Bial. Although no clinical studies with BIA 10-2474 have occurred in the U.S., FDA is conferring with the European Medicines Agency (EMA) and the French national medicines agency (ASNM). French authorities continue to investigate the events reported by Biotrial. FDA will learn as much as possible about BIA 10-2474 and the results of the French phase 1 study.

To meet FDA regulatory requirements, study sponsors collect rigorous laboratory and animal data and must submit such safety data to FDA in an IND application before any human volunteers may be enrolled in a phase 1 study. Furthermore, sponsors may not initiate phase 1 studies until 30 days after submitting an IND application to the agency. This period of time allows FDA scientists to review the safety data and determine if the proposed study is reasonably safe to proceed. If FDA determines that human subjects might be exposed unnecessarily to risk of illness or injury, the study may be placed on “clinical hold” by the agency. Catastrophic adverse events in phase 1 studies conducted in the U.S. are extremely rare.

BIA 10-2474 is reported to be an inhibitor of fatty acid amide hydrolase (FAAH), an enzyme involved in cell function in the nervous system. FAAH inhibitors have been studied for their potential therapeutic use in a number of neurological disorders. This week’s tragedy in France is the first human fatality following exposure to an FAAH inhibitor.

FDA is in the process of collecting and reviewing safety information pertinent to FAAH inhibitors under investigation in the U.S. FDA will work with sponsors to ensure the safety of participants in clinical studies and take regulatory action as appropriate. FDA will also work with sponsors to ensure patients and investigators participating in clinical studies of FAAH inhibitors are fully informed regarding the risks and potential benefits of these drugs.

Source:FDA


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE